Anika Therapeutics, Inc. ANIK
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About ANIK
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Anika Therapeutics, Inc. is a U.S.-based biotechnology and medical technology company focused on developing, manufacturing, and commercializing products primarily for orthopedic care, osteoarthritis pain management, regenerative solutions, and sports medicine applications. The company operates within the broader musculoskeletal healthcare and orthopedic device industries, with a business model centered on proprietary hyaluronic acid (HA) technologies and regenerative medicine platforms. Its core revenue drivers historically have included viscosupplementation products for osteoarthritis of the knee, orthopedic regenerative products, and sports medicine and joint preservation solutions used by physicians, ambulatory surgery centers, and hospitals.
Anika was founded in 1983 and is headquartered in Massachusetts, United States. The company initially built its business around HA-based products used in osteoarthritis treatment and later expanded through internal product development and acquisitions into regenerative solutions and minimally invasive orthopedic repair technologies. Over time, Anika evolved from a single-product viscosupplementation company into a diversified orthopedic-focused organization with offerings spanning pain management, tissue preservation, and surgical repair technologies. Its strategic positioning is supported by long-standing expertise in HA chemistry, manufacturing capabilities, and relationships within orthopedic and sports medicine markets.
Business Operations
Anika organizes its operations primarily around orthopedic and regenerative medicine product categories. Its business includes products and technologies associated with osteoarthritis pain management, regenerative solutions, and sports medicine repair and preservation procedures. Key commercial offerings have included injectable HA products, tissue preservation technologies, and orthopedic repair systems. The company derives revenue from direct product sales, distribution partnerships, and international commercialization arrangements. Its customer base includes orthopedic surgeons, sports medicine specialists, healthcare providers, and medical distributors.
The company maintains operations in both domestic and international markets, with products sold across the United States, Europe, and select international regions. Anika controls proprietary HA manufacturing technologies and regenerative medicine assets that support product development and commercialization. Strategic acquisitions expanded its orthopedic surgery portfolio, including the acquisition of Arthrosurface, which added joint preservation and resurfacing technologies, and Parcus Medical, which strengthened its sports medicine and surgical repair capabilities. These businesses have been integrated into Anika’s broader orthopedic platform to support procedural growth and surgeon adoption.
Strategic Position & Investments
Anika’s strategic direction has focused on expanding beyond legacy viscosupplementation products into higher-growth orthopedic and sports medicine markets. The company has invested in regenerative medicine technologies, minimally invasive orthopedic procedures, and tissue repair solutions intended to improve joint preservation and musculoskeletal outcomes. Management has emphasized building a diversified orthopedic portfolio with recurring procedural demand and broader surgeon engagement across care settings.
Major investments and acquisitions have included Arthrosurface and Parcus Medical, both of which expanded Anika’s product portfolio and market access in orthopedic surgery and sports medicine. The company has also invested in product innovation related to regenerative solutions, soft tissue repair, and HA-based therapeutic technologies. Its strategic emphasis has included integrating acquired technologies into a unified commercial platform while increasing penetration in ambulatory surgical centers and outpatient orthopedic care. Public filings and investor communications indicate continued focus on innovation-driven growth within orthopedic and regenerative medicine sectors.
Geographic Footprint
Anika Therapeutics is headquartered in Bedford, Massachusetts, and maintains a commercial presence across multiple international regions through direct operations, distribution agreements, and commercial partnerships. The company’s largest market is the United States, where it markets orthopedic and regenerative products to healthcare providers and surgical facilities. It also maintains product distribution and commercial relationships in parts of Europe, Asia-Pacific, and other international healthcare markets.
The company’s global footprint has historically been influenced by demand for HA-based osteoarthritis products and expanding orthopedic procedure adoption internationally. International revenue contributions have varied over time depending on distribution arrangements, reimbursement environments, and regulatory approvals in different countries. Anika’s operational and commercial strategy reflects an effort to balance domestic orthopedic growth with selective international expansion opportunities in musculoskeletal healthcare.
Leadership & Governance
Anika Therapeutics is governed by a board of directors and executive leadership team focused on orthopedic innovation, operational execution, and long-term portfolio diversification. The company’s leadership strategy has emphasized transitioning Anika from a primarily viscosupplementation-focused organization into a broader orthopedic and regenerative medicine company. Public company governance practices are guided through disclosures in SEC filings, including annual reports and proxy statements.
Key executives include:
- Cheryl R. Blanchard – Former President and Chief Executive Officer
- Michael M. Pereira – Chief Financial Officer
- Kevin Stone, M.D. – Board member associated with orthopedic and sports medicine expertise
- Joseph Darling – Former Chief Commercial Officer
- Robert M. Walsh – Chairman of the Board
Leadership roles and executive composition have evolved over time as part of the company’s broader strategic transformation initiatives. Certain executive appointments and transitions may vary based on the most recent reporting periods and public disclosures.